Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.35 |
| ▸ | ACLY | P53396 | 3/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23348472 | 0.91 | PGR (0.35) | PGRACLYCYP11B1CYP11B2FLT3 | |
| SCHEMBL23348413 | 0.91 | KIF11 (0.35) | PGRACLYPTPN5KIF11 | |
| SCHEMBL23348466 | 0.86 | CHEK1 (0.37) | ACLYSMN1; SMN2HIF1A | |
| SCHEMBL22156823 | 0.86 | PGR (0.38) | PGRACLYCYP11B1CYP11B2FLT3 | |
| SCHEMBL22156828 | 0.86 | ACLY (0.37) | PGRACLYCYP11B1CYP11B2FLT3 | |
| SCHEMBL23348253 | 0.86 | EGLN2 (0.38) | EGLN2 | |
| SCHEMBL22158380 | 0.85 | PGR (0.36) | PGRACLYCYP11B1CYP11B2FLT3 | |
| SCHEMBL22158378 | 0.85 | ACLY (0.35) | PGRACLYCYP11B1CYP11B2FLT3 | |
| SCHEMBL23348310 | 0.84 | PGR (0.38) | PGRACLYEGLN2CYP11B1CYP11B2 | |
| SCHEMBL23348469 | 0.84 | SMN1; SMN2 (0.36) | ACLYEGLN2CYP11B1CYP11B2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139425-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139425-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CCND2, CCND1, CRY1 | PGR 2039/4885ACLY 3957/4885EGLN2 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.